Bukwang Pharmaceutical announced on the 19th that it has strengthened its ESG (Environmental, Social, and Governance) management and newly launched its website.
Bukwang Pharmaceutical has established a new ESG section on its renewed website and plans to actively enhance its ESG management. The ESG section is composed of five categories under Bukwang Pharmaceutical’s philosophy of "contributing to the stability of pharmaceutical supply and benefiting society through the production of excellent pharmaceuticals": Environmental Management, Social Responsibility Management, Governance & Ethical Management, ESG Bulletin Board, and Cyber Ombudsman. Each category provides a clear overview of various activities and mid- to long-term goals related to ESG management.
First, the Environmental Management (E) section consists of ▲Environmental Policy and Goals ▲Environmental Management System ▲Safety and Health Management ▲Green Purchasing. The Environmental Management System category emphasizes that Bukwang Pharmaceutical has established and operates the international environmental management standard ISO14001. Through these efforts, Bukwang Pharmaceutical has recorded zero violations of environmental laws and regulations over the past three years. Additionally, the company outlined core strategies and tasks to participate in the national goal of ‘2050 Carbon Neutrality.’ Based on this, Bukwang Pharmaceutical plans to reduce greenhouse gas emissions by 20% by 2025, 50% by 2030, 60% by 2035, and achieve carbon neutrality by 2050.
In the Social Responsibility Management (S) section, the categories are subdivided into ▲Labor and Human Rights ▲Social Contribution ▲Safety and Health Management ▲Sustainable Supply Chain, detailing the current operations and goals for each. Notably, the company disclosed major safety and health activities from last year in detail and presented mid- to long-term goals, including a commitment to maintain zero serious accidents until 2035 by continuously advancing safety prevention activities.
Lastly, the Governance & Ethical Management (G) section is classified into ▲Governance ▲Ethical Management ▲Anti-Corruption Management ▲Compliance Program ▲Information Security, transparently disclosing the management status of each. Currently, Bukwang Pharmaceutical operates a CP (Compliance Program) committee composed of professional members with minimal conflicts of interest to comply with the Fair Trade Compliance Program. The CP committee makes multifaceted efforts to promote Bukwang Pharmaceutical’s ethical management culture, including reviewing CP regulation compliance, revising operational regulations, and conducting training.
A representative from Bukwang Pharmaceutical stated, “We have newly established the ESG section to transparently disclose the activities and goals of each ESG management sector to various stakeholders such as customers, shareholders, and employees. We will continue to make steady efforts in ESG management and plan to publish a sustainable management report reflecting ESG management values, starting with the website.”
Meanwhile, Bukwang Pharmaceutical’s website underwent a major renewal along with the establishment of the ESG section. This renewal enhanced the user interface (UI) and user experience (UX) to allow easy and convenient access to Bukwang Pharmaceutical’s diverse pipelines and research and development (R&D) status.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
